Experiment 69645

Worktypes

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEchinacea purpurea (ASTERACEAE)
CitationSPERBER,SJ: SHAH,LP: GILBERT,RD: RITCHEY,TW: MONTO,AS:. (2004). ECHINACEA PURPUREA FOR PREVENTION OF EXPERIMENTAL RHINOVIRUS COLDS.. 38(10)
Amount utilized
Compound isolated
DiseaseEXPOSURE TO RHINOVIRUS DID NOT DECREASE THE RATE OF INFECTION; HOWEVER, BECAUSE OF THE SMALL SAMPLE SIZE, STISTICAL HYPOTHESIS TESTING HAD RELATIVELY POOR POWER TO DETECT STATICALLY SIGNIFICANT DIFFERENCES IN FREQUENCY AND SEVERITY OF ILLNESS. TOTAL OF 92% OF ECHINACEA RECIPIENTS AND 95% OF PLACEBO RECIPIENTS WERE INFECTED. COLDS DEVELOPED IN 58% OF ECHINACEA RECIPIANTS AND 82% OF PLACEBO RECIPIANTS(P=.114, BY FISHER'S EXACT TEST). ADMINISTRATION OF ECHINACEA BEFORE AND AFTER 3 TIMES A DAY, FOR 7 DAYS BEFORE AND 7 DAYS AFTER INTRANASAL INOCULATION WITH RV-39. SYMPTOMS WERE ASSESSED TO EVALUATE CLINICAL ILLNESS. VIRAL CULTURE AND SROLOGIC STUDIES WERE PERFORMED TO EVALUATE THE PRESENCE OF RHINOVIRUS INFECTION. A A RAMDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL WAS CONDUCTED TO EVALUATE THE ABILITY OF ECHINACEA PURPUREA TO PREVENT INFECTION WITH RHINOVIRUS TYPE 39 (RV-39). 48 PREVIOUSLY HEALTHY ADULTS RECEIVED ECHINACEA OR PLACEBO. 2.5 ML
Dose amount7.5 ML
Number1
Qualitative resultEQUIVOCAL
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE
ExtractHYDRO-ALCOHOLIC EXT
GenderGIVEN TO BOTH SEXES